Skip to main content Back to Top

irAE Potpourri: A Little Bit of This and That for Anyone and Everyone

Broadcast Date: January 28, 2022


Subscribe on iTune PodcastsListen on Google PlaySubscribe to Stitcher Podcasts Listen on Spotify Subscribe to TuneIn PodcastsSubscribe to iHeartRadio

This discussion is meant to be informative for pharmacists who are less familiar with immunotherapy-related adverse events, as well as to offer insight into decision making in challenging situations related to managing irAEs.


Jordan McPhersonJordan McPherson, Pharm.D., M.S., BCOP is Oncology Clinical Pharmacist in the ambulatory solid tumor clinics at the Huntsman Cancer Institute, an NCI designated cancer hospital, at the University of Utah Health and Adjunct Assistant Professor at the University of Utah College of Pharmacy in Salt Lake City, Utah. Dr. McPherson specializes in the treatment of skin cancer using immunotherapy and other targeted therapies. He serves as a Panelist on the NCCN Guidelines for Management of Immune Checkpoint Inhibitor-Related Toxicities, and is Past President of the Utah Society of Health-System Pharmacists. Dr. McPherson’s research efforts are well published in peer reviewed journals, including the Journal of Clinical Oncology, Journal for ImmunoTherapy of Cancer, and Pharmacotherapy.

 Tonya SmithTonya Smith, Pharm.D., BCPS, is Clinical Pharmacy Specialist in Internal Medicine at Emory University Hospital Midtown in Atlanta, Georgia. Dr. Smith received her Pharm.D. degree from the Medical University of South Carolina in Charleston, South Carolina. She completed her PGY1 Pharmacy Practice Residency and PGY2 Internal Medicine Pharmacy Residency at University of Utah Health in Salt Lake City, Utah. Prior to Emory, Dr. Smith practiced on the inpatient medical oncology service and the Supportive Oncology & Survivorship Clinic at the Huntsman Cancer Institute in Salt Lake City, Utah.


Relevant Financial Relationship Disclosures

No relevant financial relationship with an ineligible company as defined by the Standards of Integrity and Independence in Accredited Continuing Education definition of ineligible company. All relevant financial relationships have been mitigated prior to the activity.


The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This podcast is provided by ASHP and supported by an independent medical education grant from Merck, Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.